ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

A prospective Phase II clinical study to assess the efficacy and toxicity of high dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (allo- or autoSCT) as treatment of primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL) - ASTRAL

Study Overview

• Status: Completed
• Conditions: Lymphoma, B-Cell; Lymphoma, T-Cell; Aggressive Non-hodgkin Lymphoma (aNHL)
• Intervention / Treatment: Drug: High dose chemotherapy before allogeneic stem cell transplantation (alloSCT); Procedure: Bone marrow histology; Diagnostic test: clinical and laboratory parameters; Diagnostic test: PET-CT or CT

Detailed Description

This is a clinical study to assess the treatment (efficacy and toxicity) with a high dosed chemotherapy followed by stem cell transplantation in patients suffering from primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL)

After end of the active study phase, patients will receive further standard medical care at the discretion of the treating physician. The clinical consultants will provide advice on further treatment if requested.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 2

Contacts and Locations

Study Locations

• Germany
  • Augsburg, Germany
    • Klinikum Augsburg, Medizinische Klinik II
  • Bochum, Germany, 44892
    • Medizinisches Universitätsklinikum
  • Chemnitz, Germany, 09116
    • Klinikum Chemnitz gGmbH
  • Dresden, Germany
    • Universitätsklinikum Carl Gustav Carus Dresden, Medzinische Klinik I
  • Düsseldorf, Germany, 40225
    • Universitäsklinikum Düsseldorf
  • Göttingen, Germany, 37075
    • Universitätsmedizin Göttingen Klinik für Hämatologie/Med. Onkologie
  • Halle, Germany, 06120
    • Universitätsklinikum Halle
  • Hamburg, Germany, 20246
    • Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie, Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
  • Heidelberg, Germany, 69120
    • Universitätsklinikum Heidelberg, Medizinische Klinik, Innere Medizin V
  • Jena, Germany, 07747
    • Universitätsklinikum Jena, Klinik für Innere Medizin, Abtl. Hämatologie und Innternistische Onkologie
  • Münster, Germany, 48149
    • Universitätsklinikum Münster, KMT-Zentrum/ Med. Klinik A
  • Stuttgart, Germany, 70174
    • Klinikum Stuttgart
  • Brandenburg
    • Berlin, Brandenburg, Germany, 13125
      • HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Subjects must fulfill all of the following criteria to be included in this trial:

1. Provision of written informed consent and specifically the consent to the collection and processing of health-related data
2. Age: 18 years and older
3. Gender: Male and female patients
4. Histology

5. Diagnosis of relapsed or primary progressive aggressive B- or T-cell lymphoma including:

   1. B-Cell non-hodgkin lymphoma (B-NHL) or
   2. T-Cell non-hodgkin lymphoma (T-NHL):
6. Staging at relapse or progression (data should not be older than 4 weeks):
7. Staging after 2 or 3 cycles of salvage treatment:
8. Donor availability:

9. Females of childbearing potential (FCBP) must:

   • Understand the potential teratogenic risk to the unborn child
   • Understand the need and agree to utilize two reliable forms of contraception
   • Understand and agree to inform the investigator if a change or stop of method of contraception is needed
   • Be capable of complying with effective contraceptive measures
   • Be informed and understand the potential consequences of pregnancy and the need to notify her study doctor immediately if there is a risk of pregnancy
   • Understand the need to commence the study treatment as soon as study drug is dispensed following a negative pregnancy test
   • Understand the need and accept to undergo pregnancy testing based on the frequency outlined in this protocol
   • Agree to abstain from breastfeeding during study participation

10. Males must:

    • Agree to use a latex condom during any sexual contact with females of childbearing potential
    • Agree to refrain from donating semen or sperm while on the study drugs and should seek for sperm cryopreservation before therapy is started and should not father a child while treated and during one year after end of study treatment
11. Females of non-childbearing potential:

Exclusion Criteria:

Subjects are to be excluded from the study if they display any of the following criteria:

1. Pregnant females; lactating women must end breast feeding before start of study treatment
2. Serious accompanying disorder or impaired organ function
3. Central nervous system (CNS) involvement of lymphoma - to be examined in case of clinical symptoms
4. History of severe cardiac diseases, and cardiac function impairment
5. Severe kidney disease
6. HIV-positivity
7. Hepatitis B and C as defined by seropositivity
8. Patients under legal guardianship regarding medical decisions
9. Ongoing treatment or study procedures within any other clinical trial with the exception of follow up
10. Ongoing exclusion periods of other clinical studies after end of treatment
11. In patients tested: Metabolic Computer tomography (CR) in a positron emission tomography-Computer tomography (PET-CT) scan after the last cycle of therapy prior to planned SCT
12. Subjects with known hypersensitivity to the study drugs
13. Criteria which in the opinion of the investigator precluded participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety
14. Commitment to an institution by virtue of an order issued either by the judicial or the administrative authorities
15. Dependency on the sponsor, trial site or investigator

16. Additional exclusion criteria with respect to summary of product characteristics (SmPC) of the investigational medical product (IMPs) fludarabine, thiotepa, cyclophosphamide:

    1. Known hypersensitivity to fludarabine, thiotepa, cyclophosphamide or one of their metabolites
    2. Renal impairment
    3. Decompensated haemolytic anaemia
    4. Concurrent application of vital vaccines
    5. Cystitis
    6. Renal tract obstruction
    7. Active and uncontrolled infection

    8. Notice: myelosuppression and impaired hematopoietic function is not an exclusion criterion as this usual contraindication to the application to any of the IMPs will be overcome by the stem cell transplantation following conditioning therapy.

       -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: alloSCT; defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)

Drug: High dose chemotherapy before allogeneic stem cell transplantation (alloSCT); High-dose therapy (HDT) prior to alloSCT will consist of FTC; Other Names: fludarabine, thiotepa ,cyclophosphamide (FTC); Procedure: Bone marrow histology; Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved; Diagnostic test: clinical and laboratory parameters; During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.; Diagnostic test: PET-CT or CT; Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of efficacy variables, Rate of Progression free survival (PFS)	To compare a defined high dose therapy (HDT) with study medication followed by alloSCT lead to treatment results in terms of PFS, that are better than results obtained with high-dose therapy and autoSCT in a comparable Patient Population ( historical data).	1 year after SCT

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of efficacy variables, Rate of complete remissions (CR)	Number of complete remissions divided by the number of patients (CR),	1 year after stem cell transplantation (SCT)
Measurement of efficacy variables, Rate of partial remissions (PR)	Number of partial remissions divided by the number of patients (PR);	1 year after SCT
Measurement of efficacy variables, Rate of complete and partial remissions (ORR)	Number of complete and partial remissions divided by the number of patients (ORR);	1 year after SCT
Measurement of efficacy variables, Rate of progressive diseases (PD)	Number of progressive diseases after SCT divided by the number of patients (PD);	1 year after SCT
Measurement of efficacy variables, Rate of relapse (RR)	safety item	1 year after SCT
Measurement of efficacy variables, Rate of treatment-related mortality	treatment-related death divided by the number of patients	1 year after SCT
Rate of event free survival at 1 year (EFS)	safety item	1 year after SCT
Measurement of efficacy variables, Rate of overall survival at 1 year (OS)	safety item	1 year after SCT
Measurement of efficacy variables, Rate of non-relapse mortality (NRM)	safety item	1year after SCT
Measurement of efficacy variables, Causes of death	safety item	1year after SCT
Measurement of efficacy variables, Incidence and severity of acute and chronic graft versus host disease (GvHD);	safety item	until the last Follow-Up Visit ( 1-2 Year after SCT)
Measurement of efficacy variables, Adverse events (AEs) grade 3 and 4	safety item	until about day 100 after SCT.
Measurement of efficacy variables, Serious adverse events (SAEs)	safety item	until about day 100 after SCT.
Measurement of number of blood cells	recovery of White blood cells and platelets	1year after SCT
Measurement of efficacy variables, Rate of infections	safety item	1year after SCT

Collaborators and Investigators

• Sponsor: GWT-TUD GmbH
• Investigators: Principal Investigator: Bertram Glass, Prof. Dr., Helios Klinikum Berlin-Buch

Study record dates

Study Major Dates

• Study Start (Actual): June 24, 2019
• Primary Completion (Actual): March 30, 2022
• Study Completion (Actual): February 2, 2023

Study Registration Dates

• First Submitted: July 31, 2019
• First Submitted That Met QC Criteria: October 8, 2019
• First Posted (Actual): October 10, 2019

Study Record Updates

• Last Update Posted (Actual): May 24, 2023
• Last Update Submitted That Met QC Criteria: May 23, 2023
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Aggression; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Cyclophosphamide; Fludarabine; Thiotepa
• Other Study ID Numbers: ASTRAL / GLA-aNHL-R1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No